Ongoing treatment(s)-Hormonal therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...

Read More

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients.  Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Read More

Aromatase inhibitors versus tamoxifen following chemotherapy for perimenopausal women with breast cancer

Aromatase inhibitors versus tamoxifen following chemotherapy for perimenopausal women with breast cancer

Posted by on Jul 31, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to assess the use of aromatase inhibitors (AI) versus tamoxifen (Novaldex) for women before menopause with estrogen receptor-positive (ER+) breast cancer (BC). The authors found that AIs were associated with better outcomes than tamoxifen in these patients.  Some background About 80% of all BCs...

Read More

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality. Some background Prostate cancer is often treated with radiation therapy to...

Read More

Reviewing common effects of hormonal therapy in patients with breast cancer.

Reviewing common effects of hormonal therapy in patients with breast cancer.

Posted by on May 23, 2021 in Breast cancer | 0 comments

In a nutshell This article reviewed the common side effects of estrogen deprivation during hormonal therapy for women with breast cancer and provided an update on alternative therapies to manage these symptoms. Some background Breast cancer (BC) is one of the most common cancers affecting women worldwide. Some BC cells grow in response to female...

Read More

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Posted by on May 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...

Read More

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Posted by on Mar 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo. Some...

Read More

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Posted by on Mar 5, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of bicalutamide (Casodex) to enzalutamide (Xtandi), both in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The comparison showed that enzalutamide with ADT improves the outcomes particularly in Black men with mHSPC.  Some...

Read More

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Posted by on Jan 17, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC).   This study concluded that this combination provided positive outcomes for...

Read More

Aerobic and resistance training can relieve pain and improve lung-heart-function in breast cancer survivors receiving hormone therapy

Aerobic and resistance training can relieve pain and improve lung-heart-function in breast cancer survivors receiving hormone therapy

Posted by on Dec 20, 2020 in Breast cancer | 0 comments

In a nutshell This study observed the effect of different physical activities on measures like pain and cardiorespiratory fitness in patients receiving hormone therapy for breast cancer (BC). The study showed that aerobic and resistance training might positively impact cardiorespiratory fitness and pain in these patients.  Some...

Read More

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Posted by on Dec 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...

Read More

Does androgen-receptor inhibitor therapy increase the risk of falling and broken bones in patients with prostate cancer?

Does androgen-receptor inhibitor therapy increase the risk of falling and broken bones in patients with prostate cancer?

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated if treating patients who have prostate cancer with androgen receptor inhibitors (ARIs) increased their risk of falling and breaking their bones. The study found that patients who received ARI were more likely to have a fall or fracture compared to other treatments. Some background Prostate cancer (PCa)...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2021 Medivizor